ProCE Banner Activity

Modern Management of Advanced Pancreatic Cancer: Expert Answers to Frequently Asked Questions

Text Module

Expert answers to frequently asked questions about modern clinical management of pancreatic cancer, including diagnosis, screening, selecting chemotherapeutic agents, switching treatment, radiation, and surgery.

Released: September 07, 2017

Expiration: September 06, 2018

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Andrew H. Ko

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Celgene

Halozyme

Merrimack

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guidelines and clinical findings to select individualized therapies for patients with newly diagnosed advanced pancreatic cancer
  • Plan treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Manage disease- and treatment-related symptoms for patients with advanced pancreatic cancer

Program Director Disclosure

Program Director

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Celgene, Genentech, and Merrimack.

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Andrew H. Ko, MD, has disclosed that he has received consulting fees from New β Innovations and Seattle Genetics and funds for research support from Aduro Biotech, Celgene, Merrimack, and Prism Bio.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Jayoo Gokhale,

Editorial Contributor

Jayoo Gokhale, PhD, has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.